STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 2 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 PROTOCOL AGREEMENT 
 I have read the protocol specified below. In my formal capacity as Investigator, my duties 
include ensuring the safety  of the study subjects enrolled und er my supervision and providing the 
Sponsor-Investigator with complete and timely information, as outlined in the protocol.  It is understood that all information pert aining to the study will be held strictly confidential and that 
this confidentiality requirement applies to all stu dy staff at this site. Furthermore, on behalf of 
the study staff and myself, I agree to maintain th e procedures required to  carry out the study in 
accordance with accepted GCP principles and to  abide by the terms of this protocol. 
 Protocol Number:  STOP2-IP-15  Protocol Title:  Standardized Treatmen t of Pulmonary Exacerbations II (STOP2) 
 Protocol Date:  November 2, 2018     
Investigator Signature  Date 
   Print Name and Title   
Site #:   
Site Name:   
Address:   
   
   
   
   
  
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 3 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 TABLE OF CONTENTS 
1 BACKGR OUND..................................................................................................................... .....................  13 
2 STUDY RATIONALE  ............................................................................................................................... .... 13 
2.1 RISK / BENEFIT ASSESSMENT  ............................................................................................................................... . 14 
3 STUDY OBJECTIVES  ............................................................................................................................... .... 16 
3.1 PRIMARY OBJECTIVE ............................................................................................................................... ............ 16 
3.2 SECONDARY  OBJECTIVES ............................................................................................................................... ....... 16 
3.3 OTHER OBJECTIVES ............................................................................................................................... .............. 16 
4 STUDY DESIGN ............................................................................................................................... .......... 16 
4.1 STUDY OVERVIEW ............................................................................................................................... ...............  16 
5 CRITERIA  FOR EVALUATION  ......................................................................................................................  17 
5.1 PRIMARY ENDPOINT ............................................................................................................................... ............ 17 
5.2 SECONDARY  ENDPOINTS ............................................................................................................................... ....... 17 
5.3 EXPLORATORY  ENDPOINTS ............................................................................................................................... .... 18 
6 SUBJECT SELECTION  ............................................................................................................................... .. 18 
6.1 STUDY POPULATION  ............................................................................................................................... ............. 18 
6.2 INCLUSION  CRITERIA ............................................................................................................................... ............ 18 
6.3 EXCLUSION  CRITERIA ............................................................................................................................... ............ 19 
6.4 STUDY SPECIFIC TOLERANCE  FOR INCLUSION /EXCLUSION  CRITERIA ..............................................................................  19 
6.5 SCREEN FAIL CRITERIA ............................................................................................................................... .......... 19 
7 CONCURRENT  MEDICATIONS  ...................................................................................................................  20 
7.1 ALLOWED MEDICATIONS  AND TREATMENTS  ............................................................................................................  20 
7.2 PROHIBITED  MEDICATIONS  AND TREATMENTS  .........................................................................................................  20 
8 STUDY TREATMENTS  ............................................................................................................................... . 21 
8.1 METHOD OF ASSIGNING  SUBJECTS TO RESPONSE GROUP AND TREATMENT ARMS ................................................  21 
8.2 ANTIBIOTIC  SELECTION ............................................................................................................................... ......... 21 
8.3 TREATMENT  LOCATION ............................................................................................................................... ......... 21 
8.4 MEASURES OF TREATMENT  COMPLIANCE  ................................................................................................................  22 
9 STUDY PROCEDURES  AND GUIDELINES  .....................................................................................................  22 
9.1 CLINICAL ASSESSMENTS  ............................................................................................................................... ........ 22 
9.2 COLLECTION  OF CLINICAL CARE LABORATORY  RESULTS ..............................................................................................  24 
9.3 RESEARCH LABORATORY  MEASUREMENTS  ...............................................................................................................  24 
10 EVALUATIONS  BY VISIT .............................................................................................................................  25 
10.1 VISIT 1 (DAY 1) ............................................................................................................................... .............. 25 
10.2 VISIT 2 (DAY 7‐10 ±1 DAYS) ...........................................................................................................................  26 
10.3 VISIT 3 (FOLLOW‐UP 2 WEEKS AFTER SCHEDULED COMPLETION  OF IV TREATMENT  /DAY 24 – 35 +/‐2 DAYS) ........ 26 
11 ADVERSE  EXPERIENCE  REPORTING  AND DOCUMENTATION  ......................................................................  27 
11.1 ADVERSE EVENTS ............................................................................................................................... ........... 27 
11.2 SERIOUS ADVERSE EXPERIENCES  (SAE) ..............................................................................................................  28 
11.3 MEDICAL MONITORING  ............................................................................................................................... ... 29 
12 DISCONTINUATION  AND REPLACEMENT  OF SUBJECTS  ..............................................................................  29 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 4 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 12.1 EARLY WITHDRAWAL  OF SUBJECTS FROM THE STUDY ...........................................................................................  29 
12.2 REPLACEMENT  OF SUBJECTS ............................................................................................................................  29 
13 PROTOCOL  VIOLATIONS  ...........................................................................................................................  30 
14 DATA SAFETY MONITORING  .....................................................................................................................  30 
15 STATISTICAL  METHODS  AND CONSIDERATIONS  ........................................................................................  30 
15.1 DATA SETS ANALYZED ............................................................................................................................... ..... 30 
15.2 DEMOGRAPHIC  AND BASELINE CHARACTERISTICS  .................................................................................................  31 
15.3 ANALYSIS OF PRIMARY ENDPOINT .....................................................................................................................  31 
15.4 ANALYSIS OF SECONDARY  ENDPOINTS ................................................................................................................  31 
15.5 ANALYSIS OF EXPLORATORY  ENDPOINTS .............................................................................................................  32 
15.6 INTERIM ANALYSIS ............................................................................................................................... .......... 33 
15.7 SAMPLE SIZE ............................................................................................................................... ..................  33 
16 DATA COLLECTION,  RETENTION  AND CLINICAL MONITORING  ...................................................................  34 
16.1 DATA COLLECTION  INSTRUMENTS  .....................................................................................................................  34 
16.2 DATA MANAGEMENT  PROCEDURES  ..................................................................................................................  34 
16.3 DATA QUALITY CONTROL AND REPORTING .........................................................................................................  35 
16.4 SECURITY AND ARCHIVAL OF DATA ....................................................................................................................  35 
16.5 AVAILABILITY  AND RETENTION  OF INVESTIGATIONAL  RECORDS ................................................................................  35 
16.6 MONITORING  ............................................................................................................................... ................  36 
16.7 SUBJECT CONFIDENTIALITY  ..............................................................................................................................  36 
17 ADMINISTRATIVE,  ETHICAL, REGULATORY  CONSIDERATIONS  ...................................................................  36 
17.1 PROTOCOL  AMENDMENTS  ...............................................................................................................................  36 
17.2 INSTITUTIONAL  REVIEW BOARDS ......................................................................................................................  36 
17.3 INFORMED  CONSENT FORM .............................................................................................................................  37 
17.4 CONSENT FOR COLLECTION  AND USE OF CFF REGISTRY ID NUMBER (US SITES ONLY) ................................................  37 
17.5 PUBLICATIONS  ............................................................................................................................... ...............  38 
17.6 INVESTIGATOR  RESPONSIBILITIES  .......................................................................................................................  38 
18 REFERENCES  ............................................................................................................................... ..............  39 
19 APPENDIX  1. SCHEDULE  OF EVENTS ..........................................................................................................  41 
 
  
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 5 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 LIST OF ABBREVIATIONS AND ACRONYMS 
AE adverse event 
ANOVA Analysis of variance 
CF cystic fibrosis 
CFF Cystic Fibrosis Foundation 
CFFNPR Cystic Fibrosis Foundation National Patient Registry 
CFFT Cystic Fibrosis Foundation Therapeutics 
CFR Code of Federal Regulations 
CFRSD Cystic Fibrosis Respir atory Symptoms Diary 
CRISS Chronic Respiratory Infection Symptom Score 
CFTR cystic fibrosis transmem brane conductance regulator 
CRF case report form 
CRP C-Reactive Protein 
DMC Data Monitoring Committee 
DSMB Data Safety Monitoring Board 
EDC electronic data capture 
ERR Early Robust Response 
FDA Food and Drug Administration 
FEF 25%-75%  forced expiratory flow 
FEV 1 forced expiratory volume over one second 
FVC forced vital capacity 
GCP Good Clinical Practice 
GLI Global Lung Initiative 
HIPAA Health Insurance Portability and Accountability Act of 1996 
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee 
IRB Institutional Review Board 
IV intravenous 
MedDRA Medical Dictionary for Regulatory Activities 
NERR Non-Early Robust Response 
PEx pulmonary exacerbation  
PFT pulmonary function test 
SAE serious adverse experience 
TDNCC Therapeutics Development Ne twork Coordinating Center 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 6 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 PROTOCOL SYNOPSIS 
TITLE Standardized Treatment of Pulmonary Exacerbations II (STOP2) 
SPONSOR-
INVESTIGATORS Patrick Flume, MD 
Medical University of South Carolina Christopher H. Goss, MD MSc 
University of Washington 
FUNDING 
ORGANIZATION Cystic Fibrosis Foundation Therapeutics, Inc (CFFT) 
NUMBER OF SITES Approximately 60 
RATIONALE In patients with cystic fibros is (CF) who are experiencing a 
pulmonary exacerbation, a strong desire among clinicians to reduce treatment durations (and reduce co st, inconvenience, and potential 
toxicities) is in conf lict with belief that patients not responding 
robustly to treatment might benefit from extending treatment.  An assessment taken after one week of treatment has been demonstrated to predict the overall re sponse, especially for those with a robust 
improvement (Early Robust Response; ERR).  These patients are often treated with shorter courses of intravenous (IV) antibiotics in 
clinical practice and will likely experience no additional benefit from an extended IV treatment.  For thos e subjects who have a less robust 
early response to treatment, an extended treatment duration may be 
needed; however, the additional clin ical benefit of such a prolonged 
course of IV antibiotic must outwe igh potential risks of toxicity, 
treatment burden, and increas ed resource utilization. 
STUDY DESIGN This randomized, controlled, open-la bel study is designed to evaluate 
the efficacy and safety of differing dur ations of IV treatment, given in 
the hospital or at home for a pulmona ry exacerbation in adult patients 
with CF.  The study will assess the non-inferiority of 10 days versus 
14 days treatment duration among ER R subjects and the superiority 
of 21 days versus 14 days treatment duration among the subjects who do not meet the definition of ERR (non-ERR; NERR) 
Subjects will undergo pulmonary fu nction testing (spirometry) and 
complete a respiratory symptom sc ore [Chronic Respiratory Infection 
Symptom Score (CRISS)] at initiatio n of IV treatment (Baseline/ 
Visit 1) and at Day 7-10 (Visit 2) .  At Visit 2, subjects will be 
allocated to groups ERR or NERR based on their initial clinical 
response as determined by the change in forced expiratory volume in 
1 second (FEV
1; percent of predicted) and CRISS from Baseline and 
then randomized to an IV treatment  duration (nested within group).  
ERR subjects [ ≥8% predicted improvement in FEV 1 from Baseline 
(Visit 1) to Visit 2 and CRISS reduction of ≥11 points from Baseline 
(Visit 1) to Visit 2] will be random ized 1:1 to either 10 days or 14 
days total IV antibiotic  treatment duration. Remainin g (NERR) 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 7 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 subjects will be randomized 1:1 to receive either 14 or 21 days total 
IV antibiotic treatment duration.  A ll subjects will be evaluated again 
at Visit 3, 14 days following sche duled completion of IV antibiotic 
treatment. 
DURATION OF SUBJECT PARTICIPATION AND DURATION OF STUDY  Dependent on the treatment arm, subjects will be on study from 24 to 
35 days: 
 Treatment prior to randomization:  7 – 10 days 
 Treatment post-randomization: 
o ERR-10 subjects: 0 to 3 days = 10 days (±1 day) total IV 
treatment 
o ERR-14 subjects: 4 to 7 days = 14 days (±1 day) total IV 
treatment 
o NERR-14 subjects :  4 to 7 days = 14 days (±1 day) total IV 
treatment 
o NERR-21 subjects: 11 to 14 days = 21 days (±3 days) total IV 
treatment 
 Follow-up: 14 days after end of sc heduled IV antibiotic treatment 
(±2 days) 
The total duration of the study is expected to be approximately 42 
months:  41 months for subject re cruitment and 1 month for final 
subject follow-up. 
PRIMARY 
OBJECTIVE To evaluate the efficacy and sa fety of differing durations of 
IV antibiotic treatment for CF pulmonary exacerbations  ERR Group: To determine if 10 days of IV antibiotic 
treatment (ERR-10) is as safe as and not clinically inferior (in 
terms of lung function response) to 14 days of IV antibiotic 
treatment (ERR-14) among subjects meeting the ERR threshold at Visit 2.  NERR Group:  To determine if 21 days of IV antibiotic 
treatment (NERR-21) is clinical ly superior (in terms of lung 
function response) and safe, compared to 14 days of IV antibiotic treatment (NERR-14) among subjects not meeting the ERR threshold at Visit 2.
SECONDARY 
OBJECTIVES The secondary objectives are to: 
 Evaluate efficacy of differing IV antibiotic treatment durations on 
other clinical outcomes such as  weight, respiratory symptoms, 
and subsequent IV antibiotic treatments for pulmonary exacerbation. 
 Determine the feasibility, uptake an d adherence to a standardized 
protocol of antibiotic selection. 
 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 8 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 Other objectives are to:  
 Provide a study platform for ancillary studies of PEx treatment in 
adults with CF, including inve stigations into respiratory 
microbiome, health economics, and systemic inflammation. 
 Establish a biorepository of CF serum and sputum samples 
before, during and after treatment for an adult PEx for use by the 
CF research community.  
NUMBER OF SUBJECTS Approximately 1330 screened to enroll a minimum of 310 completed 
ERR subjects and a minimum of 570 completed NERR subjects 
SUBJECT SELECTION CRITERIA:  
Inclusion Criteria Inclusion Criteria: 
1. Male or female ≥18 years of age at Visit 1 
2. Documentation of a CF diagnosis as evidenced by one or more 
clinical features consistent w ith the CF phenotype and one or 
more of the following criteria: 
 Sweat chloride equal to or greater than 60 mEq/liter by 
quantitative pilocarpine i ontophoresis test (QPIT)  
 Two well-characterized mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene  
 Abnormal nasal potential diffe rence (change in NPD in 
response to a low chloride so lution and isoproteronol of less 
than -5 mV) 
3. Enrolled in the Cystic Fibrosis Foundation National Patient 
Registry (CFFNPR) prior to  Visit 1 (US sites only) 
4. At the time of Visit 1, there is a pl an to initiate IV antibiotics for a 
pulmonary exacerbation  
5. Performed spirometry at Visit 1 and Visit 2 and willing to 
perform spirometry at Visit 3 
6. Completed the CRISS questionnaire  at Visit 1 and Visit 2 and 
willing to complete the CFRSD questionnaire at Visit 3 
7. Willing to adhere to a specific treatment duration determined by 
initial response to treatment and subsequent randomization 
8. Willing to return for  follow up Visit 3 
9. Written informed consent obtained from the subject or subject’s 
legal representative 
SUBJECT SELECTION CRITERIA:  
Exclusion Criteria Exclusion Criteria: 
1. Previous randomization in this study  
2. Treatment with IV antibiotics in  the 6 weeks prior to Visit 1 
3. Admission  to the intensive care unit for current pulmonary 
exacerbation in the two weeks prio r to Visit 2, unless admission 
was due to a desensitization protocol 
4. Pneumothorax in the two weeks prior to Visit 2 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 9 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 5. Primary diagnosis for current ho spitalization is unrelated to 
worsening lower respiratory symptoms (e.g., pulmonary clean out, DIOS, sinusitis) 
6. Massive hemoptysis defined as > 250 cc in a 24 hour period or 
100 cc/day over 4 consecutive days occurring in the two weeks prior to Visit 2 
7. Current pulmonary exacerbation th ought to be due to allergic 
bronchopulmonary aspergillosis (ABPA) 
8. At Visit 1, receiving ongoing treatment with a duration of more 
than 2 weeks with prednisone  equivalent to >10mg/day  
9. History of  solid organ transplantation  
10. Receiving antimicrobial therapy to treat non-tuberculous 
mycobacterium (e.g., M. abscessus , M. avium  complex) in the 
two weeks prior to Visit 2 
TEST PRODUCT, DOSE, AND ROUTE OF ADMINISTRATION Initial IV antibiotics will be sele cted by the treati ng physician using 
study-specific guidelines provided  and taking into account prior 
sputum culture results, previous antibiotic intolerances, and known 
drug allergies.   
CONTROL PRODUCT, DOSE AND ROUTE OF ADMINISTRATION N/A 
CONCOMMITANT 
MEDICATIONS Allowed Medications and Treatments 
Chronic Therapies A stable therapeutic regimen betwee n Baseline (Visit 1) and Visit 3 is 
the goal. Ongoing chronic treatment (>21 days prior to Visit 1) with Pulmozyme
®, high dose ibuprofen, hyperton ic saline, azithromycin, 
short and long bronchodilators, airw ay clearance, and FDA approved 
CFTR modulator therapy is allowe d. Subjects that have been using 
any of these therapies chronically should be encouraged to continue 
them throughout the entire study period (through Visit 3). Any of 
these medications may be introduced  between Visit 1 and Visit 3 if 
they are intended to remain as  a chronic therapy.  Chronic 
medications can be stopped if the clinician has determined that the 
therapy is either ineff ective or doing harm.   
Continuation of ongoing chronic treatment (>21 days prior to 
screening) with inhaled or oral an tibiotics is allowed according to the 
schedule below: 
 If a subject is taking continuous  inhaled or oral antibiotics, 
they may take them anytime between Visit 1 and 3. 
 If a subject is taking cycled inhaled antibiotics, they may 
maintain their current on/off cycle, but ideally will not start a new cycle during the 14 days  prior to Visit 3.   
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 10 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 Treatment of PEx 
Treatment with corticosteroids is allowed at the discretion of the 
treating clinician for the indication of the current PEx.  However, the 
decision to use corticosteroids shou ld be made prior to randomization 
at Visit 2 as this will be incl uded as a randomization stratum.   
Subjects should perform maximally effective airway clearance 
therapies during the course of treatment for the PEx.  These will be recommended by the treating clinician. 
Following Completion of Treatment of PEx 
Corticosteroids, if init iated during the treatm ent, should be weaned 
according to the clinic ian’s usual practice. 
Prohibited Medications and Treatments 
No antibiotics (oral or inhaled) should be taken following the 
scheduled completion of the IV treat ment of PEx until after Visit 3 
except as noted in the Al lowed Medications section.  
Investigational therapies ar e prohibited during the study. 
PRIMARY 
ENDPOINT Absolute change in percent predicted FEV 1 from initiation of IV 
treatment (Baseline/Visit 1) to tw o weeks after scheduled completion 
of IV antibiotic treatment (Visit 3). 
SECONDARY 
ENDPOINTS Efficacy 
 Absolute change in CRISS from Visit 1 (Baseline) to Visit 3 
 Proportion of patients retreated  for pulmonary exacerbation 
within 30 days following scheduled  completion of IV antibiotics 
as collected in the CFFNPR 
 Time (days) to next pulmonary exacerbation following scheduled  
completion of IV antibiotics as  collected in the CFFNPR 
 Relative change in FEV 1 (liters) from Visit 1 (Baseline) to Visit 3 
 Absolute change in weight (kg) fr om Visit 1 (Baseline) to Visit 3  
Safety 
 Incidence of adverse events, in cluding clinically significant 
abnormal lab values 
 Retreatment of pulmonary ex acerbation prior to Visit 3 
Exploratory Endpoints 
 Baseline, treatment characteristic s, and outcomes (via CFFNPR) 
of the un-randomized subjects by re ason (e.g., ineligible, lost to 
follow-up)  
 Baseline, treatment characteristic s, and outcomes (via CFFNPR) 
of the randomized but lost  to follow-up subjects 
 Adherence to antibiotic selection protocol  
 Adherence to randomization scheme  
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 11 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015  C-reactive protein at all visits a nd change from Visit 1 (Baseline) 
to Visit 2 and 3  
 Health related quality of life 
 Direct and indire ct medical costs 
 Sputum microbiome 
PLANNED INTERIM 
ANALYSIS The Cystic Fibrosis Foundation Data Safety Monitoring Board 
(DSMB) will establish a Data Monitoring Committee (DMC) to 
review data relating to safety a nd efficacy, to conduct and review 
interim analyses, and to ensure th e continued scientific validity and 
merit of the study. Serious adverse events will be monitored by the committee on an ongoing basis throughout the study. 
A pre-defined monitoring plan fo r feasibility, variance estimation, 
sample size adaptation, and study sto pping rules will be formalized in 
conjunction with the DMC and will be in place prior to initiating the 
study. Feasibility will be closely monitored for the first 100 enrolled subjects to ensure adherence to  antibiotic protocol, return for 
randomization, and adherence to randomized treatment duration.  
Each group (ERR and NERR) will have  separate monitoring criteria 
and a decision to stop one may not  be conditional on the other. 
STATISTICS 
Primary Analysis Plan The primary endpoint is absolute change in percent predicted FEV 1 
from Visit 1 (Baseline) to two w eeks after scheduled completion of 
IV antibiotics (Visit 3). The pr imary endpoint will be compared 
between treatment durations within ERR and NERR groups using Analysis of Variance (ANOVA)  adjusted for dichotomous 
randomization strata: Visit 1 FEV
1, number of IV-treated 
exacerbations in prior year, locati on of IV administration by Visit 2, 
and use of systemic corticosteroids by Visit 2.  
The treatment effect for each group (ERR and NERR) (estimated via 
adjusted ANOVA least squares means)  will be presented along with 
corresponding 95% confidence interval s. Observed treatment effect 
and the 95% CI will provide primar y inference and evidence of non-
inferiority, superiority, or lack thereof in both the ERR and NERR 
groups.   
ERR Group: The non-inferiority of ERR-10 versus ERR-14 will be 
tested against a 3.5% predicted non- inferiority margin with a two-
sided 0.05 level of significance.  
NERR Group: The superiority of NERR-21 versus NERR-14 will be 
tested with a two-sided 0.05 level of significance. 
Further details will be provided in the Statistical Analysis Plan (SAP).
 
Rationale for Number 
of Subjects ERR Group: 
A non-inferiority design to sh ow that the change in FEV 1 between 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 12 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 Visit 1 and Visit 3 in the ERR subj ects who received 10 days of 
treatment (ERR-10) is no more than 3.5% predicte d less than ERR 
subjects who received 14 days tr eatment (ERR-14) requires 310 
subjects (155 per arm) who complete  the study.  ST OP pilot data 
indicate a mean change (SD) in FEV 1 between Baseline and Day 28 in 
patients with an early response to be 12.5 % predicted, 95% CI [9.5, 
15.6]. Assuming  two-sided alpha =0.05, standard deviation =9.0% 
predicted and the true difference be tween two groups is zero, the ERR 
study has 93% power to detect a 3. 5 % non-inferiority margin which 
preserves 72% of the treatment effe ct or 63% of the lower bound of 
treatment effect observed in the STOP pilot.   
NERR Group: A superiority design to show  that the ch ange in FEV
1 between Visit 1 
and Visit 3 in NERR su bjects who received 21 days treatment 
(NERR-21) is at least 2.5% predic ted greater than NERR subjects who 
received 14 days treatment (NERR-14 ) requires 570 su bjects (285 per 
arm) who complete  the study.  STOP pilo t data indicate a mean 
change (SD) in FEV 1 between Baseline and Day 28 in patients 
without an early re sponse to be 4.0% predic ted, 95% CI [1.9, 6.1].  
Assuming two-sided alpha =0.05 and standard deviation =9.0% 
predicted, the NERR study has 91% power to detect a 2.5% greater increase in FEV
1 among those treated with 21 days compared to 14 
day IV antibiotic. Because this tria l will enroll a sl ightly different 
patient population (including home IV, excluding patients who receive 
<7 days of IV antibiotics), a blinde d, interim assessment of change in 
FEV 1 % predicted and variance (poo led) will be performed and 
expected sample size may be adjusted for either the ERR or NERR 
groups. 
Based on STOP pilot data , we anticipate 1: 2 allocation of subjects into 
the ERR and NERR  groups. To meet the en rollment goal of a 
minimum of 310 completed ERR subjects and a minimum of 570 
completed NERR subjects), we wi ll screen approximately 1330 
subjects. Of these, we  expect approximately 1236 subjects will be 
enrolled and randomized (assumin g a conservative 7% drop-out rate 
between Visit 1 and Visit 2) and a minimum of 310 completed ERR 
subjects and a minimum of 570 completed NERR subjects 
(assuming an approximate 4% drop-o ut rate between Visit 2 and Visit 
3). 
 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 13 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 1 BACKGROUND 
Cystic fibrosis (CF), a life-shortening genetic disease, is marked by acute episodes during 
which symptoms of lung infect ion increase and lung function  decreases, termed pulmonary 
exacerbations (PEx).  PEx ar e associated with reduced health-related quality of life1-3 
accelerated pulmonary function decline4 and decreased survival5-8, and are commonly treated 
with antibiotics and supportive respiratory care.  The incidence of PEx appears to be relatively 
constant over the life of a CF patient, but antibiotic tr eatments change as patient airway 
infections become more comple x and lung disease advances.9  In adolescents and adults, the 
proportions of PEx that are treated with in travenous (IV) antibiotic s steadily increases.9,10  
There has been no consensus as to how long to treat PEx with  IV antibiotics and treatment 
durations can range fr om days to weeks.11 Cystic fibrosis consensu s pulmonary gu idelines for 
the treatment of PEx sponso red by the Cystic Fibrosis  Foundation (CFF) in 200912 provided 
recommendations for PEx treatment and also identified key ques tions for which additional 
studies were needed, including whether there was an optimal duration of IV antibiotic 
treatment for CF pulmonary exacerbation. 
2 STUDY RATIONALE 
Clinical trials provide the strong est evidence for medical decisions and are relie d upon for evidence-
based treatment guidelines. Performing these trials  can be expensive and bu rdensome; they typically 
require a specialized infr astructure that includes  multiple sites w ith investigator s and research 
coordinators, oversight providing intensive review of study protocols and study conduct, and development of rigorous data co llection systems that require valid ation for accuracy. Because of the 
expense, many important questions may never be addres sed.  This is especia lly true for comparison 
of therapies within the context of comparative effectiveness research (CER) studies.  These 
challenges are especially troublesome for those who treat patients with an orphan disease, such as 
CF.  Because there are fewer patient s, studies require an even greater  number of sites, often driving 
up the expense.  Wh at are needed are innovati ve study designs that allow for gr eater flexibility, 
taking advantage of existing infras tructures to speed up the conduct of the tria l and to reduce the 
overall cost.   
An acute drop in pulmonary functio n is highly associated with th e diagnosis and treatment of PEx
13 
and treatment with IV antibiotics has been shown to result in improved lung function in CF patients 
experiencing PEx.14  In 2011, 35.1% of patie nts of all ages followed in the Cystic  Fibrosis 
Foundation National Patient Regist ry (CFFNPR, 9,516 patients) were treated at least once with IV 
antibiotics for PEx, with the median number of IV antibiotic treatment days per PEx varying greatly 
by CF care center, from 3 da ys to 24.2 days (CFF 2012).15  Unfortunately, it ha s been estimated that 
as many as a quarter of patients wi th PEx treated with IV antibiotic s fail to return to even 90% of 
the lung function they had prior to exacerbation.16 
In 2011, the median duration of IV  antibiotic treatment for PEx in the US was 13.5 days for children 
less than 18 years of age and 14.5 days for older patients.15  There have been no objective studies of 
the effect of antibiotic tr eatment duration on patie nt response.  For this reason, it is not known 
whether very short IV antibiotic  treatment durations, apparently practiced in some US care 
centers,15 are associated with incomplete  patient responses.  Similarly, if little additional benefit is 
realized beyond about 2 weeks of  antibiotic treatment for PEx11 (as has been suggested by 
VanDevanter et al), then  IV antibiotic treatment regimens exceeding 14 days and received by 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 14 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 approximately half of US CF patients15 may only serve to increase the risk of treatment-associated 
toxicity and burden without a corresponding improvement  in health outcomes.  
Identification of an optimal IV antibiotic treatme nt duration, if one exis ts, has the potential to 
improve overall PEx treatment outcomes and at th e same time reduce toxicity and treatment burden 
associated with overtreatment for PEx.    
Recently an observational pilot study of 220 CF subjects admitted to the hospital for treatment 
of a pulmonary exacerbation was conducted (STOP)  to evaluate the variability of treatment 
durations and to identify the clinical outcome measures deem ed most important to care-givers 
in determining treatment success. The design of  the current STOP2 study has been informed by 
the first STOP study, the results of previous clini cal trials and with inpu t from both CF patients 
and clinicians obtained through surveys.  Speci fically, the proposed primary efficacy measures 
(changes in respiratory sympto ms and spirometry) are known to change within 2-4 weeks 
(previous clinical trials and the observational STOP trial); fu rthermore, the survey data 
indicated that these two measures were the mo st important in defining treatment success to 
caregivers (spirometry) and patient s (symptom resolution).   In addition, these surveys indicated 
both a strong desire to reduce treatment duration (and reduce cost, inconvenience, and potential 
toxicities) and concern about whethe r subjects might be treated for too short of a period if they 
were not responding to treatment.  The STOP2 tr ial will evaluate three different treatment 
durations (10, 14, and 21 days), but will utilize an  early assessment of response after 7 to 10 
days of treatment to determine whether to random ize a subject to a shorte r or longer duration of 
treatment.  In the observational STOP study, an assessment performed after one week of 
treatment was shown to predic t the overall response, especi ally for those with a robust 
improvement (Early Robust Response; ERR) (STO P unpublished data); these patients are often 
treated with shorter cour ses of IV antibiotics in clinical practice.  Subjects who are responding 
more slowly (Non-Early Robust Response; NERR) can be reassured they will not have early 
cessation of treatment, and that the treatment durations for subjects in the NERR groups are 
consistent with common practices.   
For practical reasons, this study must be open- label as to the treatment durations; however, 
aggregate results will be blinded and tightly contro lled until the end of the trial.  Clinical care 
will be determined by the treating physician but will adhere to recommendations in the 
standardized protocol to assu re patients are receiving optimal treatment and to reduce the 
variation in other treatment parameters. 
2.1 Risk / Benefit Assessment 
Treatment-Associated Risks:  
This is an interventional study that  will dictate the duration of IV antibiotics for the treatment of 
pulmonary exacerbation. There can be risks associ ated with the randomization as patients might 
be allocated to a duration of an tibiotic therapy that may be too short or too long.  The potential 
risk of an insufficient duration of antibiotics is an early relapse of  the exacerbation, although 
surveys of CF clinicians reveal that a majority consider any new treatment for an exacerbation, at 
any time after the previous treatment, to be a new event rather than a relapse.  The potential risks of an excess duration of antibioti cs include unnecessary cost as we ll as the potential for injury 
attributed to the treatment, specifically drug t oxicity (e.g., antibiotic-ass ociated nephrotoxicity, 
ototoxicity, neurotoxicity, a nd/or vestibular toxicity, C. difficile  colitis due to broad spectrum 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 15 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 antibiotic use) or a comp lication related to the indwelling IV ca theter (e.g., thrombus). Clinicians 
are keenly aware of these potential complications as part of standard therapy and monitor these 
risks routinely.  Generally, intravenous antibiotics  used to treat acute pulmonary exacerbation in 
CF are all well tolerated, and CF  patients have extens ive experience receiving repeated courses 
of intravenous antibiotics for acute pulmonary exacerbation.     
It is noted that the du ration of antibiotics will be 10, 14 or 21 days, which are consistent with 
current durations used to trea t patients (CFFNPR data). Of note, 50% of patients will be 
randomized to 14 days of IV antibiotics, which is the most frequently  used duration (CFFNPR 
data) and the most frequently repor ted duration by CF clinicians (sur vey data , not published).  In 
addition, the randomization is based upon the initial response to treatment such that the duration 
of antibiotics is even more likely to be consis tent with current treatment practices [i.e., patients 
with a robust response will tend to get a shorter du ration (10 vs 14 days) while those with a more 
sluggish response will tend to ge t a longer duration (14 vs. 21 days)]. This randomization 
allocation should mitigate the risks of inappropriate ly short or long durations as they will be tied 
to the initial patient response and are consistent with co mmon practice among CF clinicians. 
There are other potential risks asso ciated with antibiotic usage incl uding adverse effects that are 
non-toxic (e.g., nausea, diarrhea) as well as selection of pathog ens that are resistant to the 
therapy chosen (i.e., resistant bacter ia, fungi).  It is noted that se lection of resistant bacteria has 
been reported following standard of pract ice treatment of pulmonary exacerbations.17 The study 
Data Safety Monitoring Board (DSMB) will follow  drug-related adverse events closely in the 
clinical trial.   
All other decisions regard ing treatment of the pulmonary exa cerbation (e.g., site of treatment, 
antibiotic selection, use of ster oids) will be determined by the treating clinician.  There is a 
required assessment between days 7 and 10, which ma y not be consistent w ith the current site 
practice, but the tests performed are consistent  with standard practi ce to assess response to 
therapy (i.e., spirometry, symptom assessment) ; any additional studies performed by the site 
clinicians are at their discreti on. For these reasons, there is lit tle additional treatment-associated 
risk to patients based upon thei r participation in this study.   
Risks of Study Procedures:  All study procedures performed du ring the study are consistent with 
standard of clinical care and th ere are no perceived additional risk s in regard to physical well-
being.  During the study, there will be additiona l blood draws.  The risk of collecting blood 
includes soreness, bruising, mild pai n, mild bleeding or infection at th e site. There is also risk of 
fainting or light-headedness. Topica l application of a numbing agen t to reduce the pain from the 
blood draws will be allowed. This may cause mild sk in discoloration or swelling that resolves in 
1 to 2 hours. There is a small risk of wheezi ng, shortness of breath, and increased cough when 
performing spirometry.   
Risks to Confidentiality:  As with any research study, there is a potential risk  of breach of 
individual patient confidentiality. Study personne l at each site will enter data from source 
documents into a protocol-specific electronic Case  Report Form (CRF).  Study subjects will not 
be identified by name in the study database or on any data capture screens, but will be identified 
by initials and a subject iden tification (ID) number unique to this study. Only authorized 
individuals will be able to link the study ID to th e subject’s name (site personnel at the individual 
sites, clinical site m onitors, auditors).    
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 16 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 Potential Benefits:   As this is a randomized allocati on to a treatment duration, there is no 
anticipation that patients will realize additional benefit beyond that associated with routine 
management of their pulmonary exacerbations.  The anticipated overall benefit is definition of 
optimal treatment durations and standardized practice in the future. 
3 STUDY OBJECTIVES 
3.1 Primary Objective 
The primary objective of this study is to ev aluate the efficacy and safety of differing 
durations of IV antibiotic treatment for CF pulmonary exacerbations. Objectives for these 
two groups are as follows:  
ERR Group: To determine if 10 days of IV antibio tic treatment (ERR-10) is as safe as 
and not clinically inferior (in terms of lung function) to 14 days  of IV antibiotic treatment 
(ERR-14) among subjects meeting the ERR threshold at Visit 2. 
NERR Group:  To determine if 21 days of IV antibiotic treatment (NERR-21) is clinically 
superior (in terms of lung function) and safe, co mpared to 14 days of IV antibiotic treatment 
(NERR-14) among subjects not meeti ng the ERR threshold at Visit 2.   
3.2 Secondary Objectives 
The secondary objectives are to: 
 Evaluate efficacy of differing IV antibiotic treatment durations on other clinical outcomes 
such as weight, respiratory symptoms, and subs equent IV antibiotic treatments for pulmonary 
exacerbation. 
 Determine the feasibility, uptake and adherence to a standardized protocol of antibiotic 
selection. 
3.3 Other Objectives 
 Provide a study platform for ancillary studies of  PEx treatment in adults with CF, including 
investigations into respiratory microbiome, health economics, and systemic inflammation. 
 Establish a biorepository of CF  serum and sputum samples befo re, during and after treatment 
for an adult PEx for use by the CF research community.  
4 STUDY DESIGN 
4.1 Study Overview 
This randomized, controlled, open-label study is de signed to evaluate the efficacy and safety of 
differing durations of IV treatment, given in  the hospital or at home for a pulmonary 
exacerbation in adult patients with CF (Figure 1) .  Approximately 1330 subjects will be screened 
in an effort to enroll a minimum of 310 completed ERR subjects and a minimum of 570 
completed NERR subjects. 
The study will assess the non-inferiority of 10 da ys versus 14 days treatment duration among 
ERR subjects and the superiority of 21 days versus 14 days treatment duration among NERR 
subjects. 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 17 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 The duration of participation fo r each subject is dependent on  the response group (ERR versus 
NERR) and randomization within group.   Subject s will be on study anywhere from 24 to 35 
days. Subjects will undergo pulmonary function testing (spirometry) and complete a respiratory symptom score (CRISS) at initiation of IV treatment (Base line/Visit 1) and at Day 7-10 (Visit 2).  
At Visit 2, subjects will be allocated to groups ERR or NERR based on their initial clinical 
response as determined by the change in FEV
1 (percent of predicted) and CRISS from Baseline 
and then randomized to an IV treatment dura tion (nested within group) .  ERR subjects [those 
who have experienced ≥8% predicted improvement in FEV 1 from Baseline (Visit 1) to Visit 2 
and CRISS reduction of ≥11 points from Baseline (Visit 1) to Visit 2] will be randomized 1:1 to 
either 10 days or 14 days total IV antibio tic treatment (ERR-10 and ERR-14 arms). NERR 
subjects (who have not experienced changes fr om Visit 1 that qualify them for the ERR group) 
will be randomized 1:1 to receive either 14 or  21 days total IV antibiotic treatment (NERR-14 
and NERR-21 arms).  All subjects will be eval uated again at Visit 3, 14 days following 
scheduled completion of IV an tibiotic treatment (Figure 1). 
Total duration of the study is expected to be ap proximately 42 months:  41 months for subject 
recruitment and 1 month for final subject follow-up.  
Figure 1. STOP2 Study Schematic 
 
 
5 CRITERIA FOR EVALUATION 
5.1 Primary Endpoint 
The primary endpoint in the study is a comparison in the absolute  changes in percent predicted 
FEV 1 from initiation of IV antibiotic treatmen t at Visit 1 to two weeks after scheduled 
completion of IV antibiotic treatment (Visit 3).   
5.2 Secondary Endpoints 
Efficacy  Absolute change in CRISS from Visit 1 (Baseline) to Visit 3 
 Proportion of patients retreated for pulmona ry exacerbation within 30 days following 
scheduled completion of IV antibiotics as collected in the CFFNPR 

STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 18 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015  Time (days) to next pulmonary exacerba tion following scheduled completion of IV 
antibiotics as collected in the CFFNPR 
 Relative change in FEV 1 (liters) from Visit 1 (Baseline) to Visit 3 
 Absolute change in weight (kg) fr om Visit 1 (Baseline) to Visit 3 
Safety 
 Incidence of adverse events, including c linically significant abnormal lab values 
 Retreatment of pulmonary ex acerbation prior to Visit 3 
5.3 Exploratory Endpoints 
 Baseline, treatment characteristics, and out comes (via CFFNPR) of the un-randomized 
subjects by reason (e.g., in-eligi ble, lost to follow-up)  
 Baseline, treatment characteristics, and outcome s (via CFFNPR) of the randomized but lost 
to follow-up subjects 
 Adherence to antibiotic selection protocol  
 Adherence to randomization scheme  
 C-reactive protein at all visits  and change from Visit 1 (B aseline) to Visit 2 and 3  
 Health related quality of life 
 Direct and indire ct medical costs 
 Sputum microbiome 
6 SUBJECT SELECTION 
6.1 Study Population 
Subjects with a diagnosis of CF who meet all of the inclusion a nd none of the exclusion criteria 
will be eligible for participation in this study.   
6.2 Inclusion Criteria 
1. Male or female ≥18 years of age at Visit 1 
2. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent 
with the CF phenotype and one or more of the following criteria: 
a. Sweat chloride equal to or greater th an 60 mEq/liter by quantitative pilocarpine 
iontophoresis test (QPIT)  
b. Two well-characterized mutati ons in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene  
c. Abnormal nasal potential difference (change in NPD in response to a low chloride 
solution and isoproteronol  of less than -5 mV) 
3. Enrolled in the Cystic Fibrosis Foundation Nati onal Patient Registry (CFFNPR) prior to Visit 
1 (US sites only) 
4. At the time of Visit 1, there is a plan to ini tiate intravenous (IV) antib iotics for a pulmonary 
exacerbation  
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 19 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 5. Performed spirometry at Visit 1 and Visit 2 and willing to perform spirometry at Visit 3 
6. Completed the CRISS questionnaire at Visit 1 and Visit 2 and willing to complete the 
CFRSD questionnaire at Visit 3 
7. Willing to adhere to a specific treatment duration determined by initial response to treatment 
and subsequent randomization 
8. Willing to return for  follow up Visit 3  
9. Written informed consent obtained from the subject or subject’s legal representative 
6.3 Exclusion Criteria 
1. Previous randomization in this study  
2. Treatment with IV antibiotics in  the 6 weeks prior to Visit 1 
3. Admission  to the intensive care unit for curre nt pulmonary exacerbation in the two weeks 
prior to Visit 2, unless admission was due to a desensitization protocol 
4. Pneumothorax in the two weeks prior to Visit 2 
5. Primary diagnosis for current hospitalization is  unrelated to worsening lower respiratory 
symptoms (e.g., pulmonary clean out, DIOS, sinusitis) 
6. Massive hemoptysis defined as > 250 cc in a 24 hour period or 100 cc/day over 4 consecutive 
days occurring in the tw o weeks prior to Visit 2 
7. Current pulmonary exacerba tion thought to be due to allergic bronchopulmonary 
aspergillosis (ABPA) 
8. At Visit 1, receiving ongoing treatment with a duration of more than 2 weeks with 
prednisone equivale nt to >10mg/day  
9. History of solid organ transplantation  
10. Receiving antimicrobial therapy to treat  non-tuberculous mycobacterium (e.g., M. abscessus , 
M. avium  complex) in the two weeks prior to Visit 2 
6.4 Study Specific Tolerance for Inclusion/Exclusion Criteria 
Subjects who fail to meet one or more of the incl usion criteria or who meet any of the exclusion 
criteria will not be enrolled in this study. Waiver s of any of the above study entry criteria will not 
be granted. 
6.5 Screen Fail Criteria 
Any consented patient who is excluded from the study before randomization is considered a 
screen failure. All screen failures must be doc umented with the reason for the screen failure 
adequately stated. Screen failure s can be re-screened for this study at a subsequent pulmonary 
exacerbation. 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 20 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 7 CONCURRENT MEDICATIONS 
7.1 Allowed Medications and Treatments 
7.1.1 Chronic Therapies 
A stable therapeutic regimen between Baseline (V isit 1) and Visit 3 is the goal. Ongoing chronic 
treatment (>21 days prior to Visit 1) with Pulmozyme®, high dose ibuprofen, hypertonic saline, 
azithromycin, short and long br onchodilators, airway clearan ce, and FDA- approved CFTR 
modulator therapy is allowed. Subj ects that have been using any of these therap ies chronically 
should be encouraged to conti nue them throughout the entire st udy period (through Visit 3). Any 
of these medications may be introduced between Visit 1 and Visit 3 if they are intended to 
remain as a chronic therapy.  Chronic medications  can be stopped if the clinician has determined 
that the therapy is either ineffective or doing harm.   
Continuation of ongoing chronic tr eatment (>21 days prior to scr eening) with inhaled or oral 
antibiotics is allowed according to the schedule below: 
 If a subject is taking continuous inhaled or or al antibiotics, they ma y take them anytime 
between Visit 1 and 3. 
 If a subject is taking cycled i nhaled antibiotics, they may maintain their current on/off cycle, 
but ideally will not start a new cycle duri ng the 14 days prior to Visit 3.   
7.1.2 Treatment of PEx 
Refer to Section 8.2 Antibiotic Selection for th e study recommendations for antibiotic use.   
Treatment with corticosteroids is allowed at the discretion of the treating clinician for the 
indication of the current PEx.  However, the deci sion to use corticosteroids should be made prior 
to randomization at Visit 2 as this will be  included as a randomization stratum.   
Subjects should perform maximally effective airw ay clearance therapies during the course of 
treatment for the PEx.  These will be  recommended by the treating clinician. 
7.1.3 Following Completion of Treatment of PEx 
Corticosteroids, if initiated duri ng the treatment, should be wean ed according to the clinician’s 
usual practice. 
7.2 Prohibited Medications and Treatments 
No antibiotics (oral or inhaled) should be taken following th e scheduled completion of the IV 
treatment of PEx until afte r Visit 3 except as noted in Section 7.1.1 (above).   
Investigational therapies are prohibited dur ing the study.  The combination modulator 
ivacaftor/tezacaftor or a triple co mbination therapy is not considered an investigational therapy 
and those subjects who are on an open label extension or an Expanded Access Program will be considered eligible for STOP2 as  long as it is part of a stab le regimen (i.e., >30 days of 
treatment). 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 21 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 8 STUDY TREATMENTS 
8.1 Method of Assigning Subjects to Resp onse Group and Treatment Arms 
All eligible subjects will undergo pulmonary f unction testing (spirometry) and complete a 
respiratory symptom score (CRISS) at Baseline (Visit 1) and at Day 7-10 (Visit 2).  At Visit 2, 
subjects will be allocated to either the ERR or NERR group ba sed upon their initial clinical 
response as determined by the change from Baseline in FEV 1 (percent of predicted as determined 
by GLI equations) 18,19 and CRISS and then randomized to a treatment arm (duration nested 
within response group). The spirometry and CRISS measures must be present and entered into 
EDC for both Baseline (Visit 1) and Vi sit 2 for randomization to occur. 
ERR subjects [ ≥8% predicted improvement in FEV 1 from Baseline (Visit 1) to Visit 2 and 
CRISS reduction of ≥11 points from Baseline (Visit 1) to Visit 2] will be randomized 1:1 to 
either 10 days (ERR-10) or 14 days (ERR-14) to tal IV antibiotic treatment duration while 
remaining subjects not meeting the ERR threshol d will be randomized 1:1 to receive either 14 
(NERR-14) or 21 (NERR-21) days total IV an tibiotic treatment dura tion. A minimum of 310 
subjects (155 per duration arm) will be allocated to the ERR group and a mi nimum of 570 subjects 
(285 per duration arm) to the NERR group. Randomization will o ccur by a predetermined scheme. 
Within each response group, subjects will be stratified by Visit 1 FEV 1 (FEV 1 < 50% of 
predicted versus ≥50% predicted), number of IV-treated ex acerbations in prior year (0-1 versus 
2+ in prior year), location of  IV treatment by Visit 2 (exclusively home versus any hospital 
nights), and use of systemic corticosteroids by Visit 2. 
Randomization will occur centrally using a web based randomization system linked to the 
electronic data capture (EDC) sy stem.  Only authorized site personnel are given access to the 
EDC system. Authorized site personnel will enter subject eligibility information as well as any 
information needed for randomization stratificat ion. The system will pr ovide the appropriate 
authorized site personnel with a randomization assignment for that subject that matches a 
specific treatment duration.  
8.2 Antibiotic Selection 
Initial IV antibiotics will be selected using st udy-specific guidelines pr ovided and taking into 
account prior sputum culture results, previous anti biotic intolerances, and known drug allergies.  
Antibiotics may be changed at Visit 2 if presumed to be an in sufficient response, sooner if there 
is a rapid decline, new intolerance or drug allerg y.  Such changes should  still adhere to the 
study-specific guidelines and may represent newly identif ied pathogens in sput um cultures.  If 
an antibiotic change is made due to insufficient response, the decision to change should be made 
prior to randomizati on at Visit 2.   
Once the subject has completed the assigned IV an tibiotic duratio n, no additional oral, inhaled, 
or IV antibiotics shou ld be administered, except as spec ified in Section 7.1 above.   
8.3 Treatment Location 
The location of treatment (i.e., hom e vs. hospital) is at the discretion of the treating clinician.  
The patient may be treate d entirely at home, entirely in the hospital, or any por tion of treatment 
in the hospital with completion at home.   
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 22 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 8.4 Measures of Treatment Compliance 
Treatment compliance will be based on adherence to the study-specific antibiotic regimen and to 
the assigned duration of treatment.  The site will record antibiotic use in the Concomitant 
Medications CRF and the IV  Antibiotic Treatment CRF. 
9 STUDY PROCEDURES AND GUIDELINES 
The procedures described below will be performed at the visits noted in the Schedule of Events 
(Appendix 1) and in Section 10. 
Prior to conducting any study-re lated activities, wr itten informed consent and the Health 
Insurance Portability and Account ability Act (HIPAA) authoriza tion (if applicable) must be 
signed and dated by the subject or su bject’s legal representa tive.  If appropriate, assent must also 
be obtained prior to conducti ng any study-relate d activities. 
9.1 Clinical Assessments 
9.1.1   Concomitant Medications 
All concomitant medication and concurrent ther apies will be documented as noted in the 
Schedule of Events.  Dose, route, unit, frequenc y of administration, indi cation for administration, 
dates of medication, and administration in the ho spital or at home will be recorded on the CRF. 
9.1.2 Demographics and CFF Registry ID 
Demographic information (date of birth, sex, race ) will be recorded.  CF Registry number will be 
recorded (US sites only).  
9.1.3 Medical History  
Relevant medical history, includi ng history of current disease, ot her pertinent resp iratory history, 
and information regarding underlying diseases will be recorded. Supplemental medical history 
will be collected from the CFFNPR, if applicable.   
9.1.4 CF Diagnosis 
Diagnosis date and CF diagnosis  criteria will be recorded. 
9.1.5 Physical Examination 
A complete or abbreviated physical examinati on will be performed by a licensed professional 
(e.g., MD, NP, RN, PA) as noted in the Schedule of Events.  The abbreviated exam includes 
respiratory, cardiovascular, a nd abdominal assessments.   
After randomization, new clinically significan t abnormal physical exam findings must be 
evaluated to determine if they should be  documented as adverse events (AEs).  
9.1.6 Weight and Height   
Weight will be measured on the same scale if po ssible and recorded as noted in the Schedule of 
Events. Subjects may remain in clothes (without shoes). A standing height will be measured and 
recorded as noted in the Schedule of Events. 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 23 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 9.1.7 Spirometry 
Spirometry will be performed as noted in the Schedule of Events and in accordance with the 
current American Thoracic Society recommendati ons for the performance and interpretation of 
tests.  At Visit 1, repeat spirometry does not need  to be performed if spirometry test results are 
available within the three days prior to Visit 1.   If spirometry was performed more than 3 days 
prior to Visit 1, spirometry is required to be performed at Visit 1.  If spirometry cannot be 
performed at Visit 1, it can be  performed the next day.  
Subjects who routinely use br onchodilators should use them  consistently throughout the 
enrollment period. Standard guidelines  are noted below as a reference: 
 Subjects who routinely use short acting inhale d bronchodilators should use them 15 minutes 
to 2 hours prior to pulmonary functio n tests (PFTs) dur ing study visits. 
 Subjects who routinely use long acting bronchodila tor agents should use them 15 minutes to 
6 hours prior to PFTs during study visits. 
Spirometry (FEV 1) will be centrally standardized to th e Global Lung Initiative (GLI) percent 
predicted equations for response group allocation and analysis. 
9.1.8 Subject Questionnaire: CFRSD© 
Subjects will complete a CF-specific symptom di ary called the CFRSD as noted in the Schedule 
of Events. This diary includes 16 questions a nd takes less than 5 minutes to complete. The 
CFRSD should be administered at  the beginning of the visit. 
9.1.9 Subject Questionnaire: CRISS©   
Subjects will complete a CF-specific symptom diary called the CRISS as noted in the Schedule 
of Events. This diary includes 8 questions and ta kes less than 5 minutes to complete. The CRISS 
should be administered at the beginning of the visit. 
9.1.10    Subject Questionnaire: EQ-5D-5L 
Subjects will complete the EQ-5D-5L health ques tionnaire as noted in the Schedule of Events.  
The EQ-5D-5L is a standardized generic measur e of health status developed by the EuroQol 
Group and used in clinical and pharmacoeconomi c evaluations.  It is a self-completed 
questionnaire with five (5) descriptive questions in the areas of mobility, self-care, usual activities, pain/discomfort and anxiety/depression and a visual  analogue scale (EQ-VAS) that 
records the subject’s self-rated hea lth on a 20 cm vertical scale.  
9.1.11    Adverse Events 
Information regarding occurrence of AEs w ill be captured throughout each subject’s study 
participation, starting at randomization and endi ng once the subject has terminated from the 
study. Duration (start and end dates), grade, se riousness, outcome, treatment, and relation to 
study treatment arm will be recorded on the CRF. 
9.1.12    Signs and Symptoms Evaluation 
At Visit 1, the presence of specific signs and symptoms will be assessed and documented.  
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 24 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 9.1.13    Collection of Health Care Resource Use 
Health care resource use will be documented throughout the trial as noted in the Schedule of 
Events. Inpatient hospitali zation days, outpatient medical visi ts (primary care and specialists), 
and emergency department visits  will be collected. Indirect co sts including tr avel time to 
medical visits, caregiver time, an d IV antibiotic treatment time at home will be collected as 
noted in the Schedule of Events. Job classifica tion information for subjects and for their 
informal caregivers will al so be collected as noted in  the Schedule of Events.  
9.1.14    CFFNPR Data Entry (US Sites Only) 
For the hospitalization or home IV antibiotic treatment for the pulmonary exacerbation that 
triggers enrollment into this study, an epis ode must be complete d in the CFFNPR.   
9.2 Collection of Clinical Care Laboratory Results 
9.2.1 Respiratory Cultures for CF Pathogens 
Results from respiratory culture(s ) used to determine care for th e initial pulmonary exacerbation 
and any respiratory cultures performed as part of  clinical care during th e study will be recorded 
on the CRF. 
9.2.2 Clinical Chemistry  
Results for BUN and creatinine us ed to determine care for the in itial pulmonary exacerbation and 
any BUN and creatinine tests performed as part of  clinical care during the study will be recorded 
on the CRF. 
Results for serum glucose performed as part of clinical care for the initial pulmonary 
exacerbation and during the study will be recorded on the CRF (if more than one is performed on 
a given day, only one test pe r day will be recorded).  
9.3 Research Laboratory Measurements  
9.3.1 Blood Collection for C-Reacti ve Protein (CRP) Testing 
Blood will be obtained as noted in the Schedule of  Events and sent to each site’s clinical 
chemistry lab for determination of CRP.  
9.3.2 Sputum for Microbiome Analysis 
Expectorated sputum will be collected from subject s who are able to produce sputum as noted in 
the Schedule of Events.  The samples collected will be stored frozen at -70 to -80ºC at the site 
and batch shipped as instructed  by the Therapeutics Developmen t Network Coordinating Center 
(TDNCC).  Instructions for sp ecimen collection, processing, st orage and shipping of samples 
will be provided in the Study Laboratory Manual.  
Subjects that are enrolled at study sites located in Canada will be  excluded from the collection of 
sputum for microbiome analysis. 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 25 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 9.3.3 Specimens for Long-Term Biorepository Storage 
Approximately 7.5 mL of blood for serum aliquots will be collected for the CFFT biorepository 
as noted in the Schedule of Events.  The samples collected will be stored frozen at -70 to -80ºC 
at the site and batch sh ipped to the CFFT biorepository fo r long-term biore pository storage. 
Instructions for specimen colle ction, processing, storage and shipping of samples will be 
provided in the Study Laboratory Manual.  
Any expectorated sputum remaining after micr obiome analysis may be sent to the CFFT 
biorepository for long-term biorepository storage.  
Subjects that are enrolled at study sites located in Canada will be  excluded from the collection of 
serum specimens for long-term biorepository storage. 
10 EVALUATIONS BY VISIT 
Note: Day 1 is defined as the day IV antibiotics are initiated.  Visit 1 procedures may occur up to 
three days prior to initiation of IV antibiotic s (Day 1) or up to one  calendar day after IV 
antibiotics are initiated. 
10.1 Visit 1 
1. Review the study with the subjec t (subject’s legal representative ) and obtain written informed 
consent and HIPAA authorizati on and assent, if appropriate. 
2. Assign the subject a uni que screening number. 
3. Record demographics data and, fo r US sites, CFF Registry ID.   
4. Record medical history, includi ng a history of CF, diagnosis da te, prior CF treatments and 
number of exacerbations in the previous year.  
5. Record concomitant medications  including current and planne d systemic steroid use.  
6. Confirm that the subject will begin treatment for the PEx following recommendations in the 
treatment protocol. 
7. If a respiratory specimen for CF pathogens has be en collected for clinical care, obtain results 
and record.  
8. If Chemistry tests for BUN, creatinine and seru m glucose have been collected for clinical 
care, obtain results and record. 
9. Provide CRISS Self-Report to subject for completion. 
10. Provide EQ-5D-5L to subject for completion. 
11. Collect subject health care resource use information.  
12. Perform a complete physical examin ation by a physician or designee. 
13. Measure and record height and weight. 
14. Perform and record spirometry if not  performed within the past 3 days. 
15. If able to expectorate sputum, collect  expectorated sputum for microbiome. 
16. Collect blood and test for CRP at site.  
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 26 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 17. Collect blood and freeze serum for banking. 
18. Complete Signs and Symptoms Assessment. 
19. Schedule subject for Visit 2 to occu r on Day 7 - 10 of IV antibiotics. 
10.2 Visit 2 (Day 7-10 ±1 days) 
1. Provide CRISS Self-Report to subject for completion. 
2. Provide EQ-5D-5L to subject for completion. 
3. Measure and record weight. 
4. Perform and record spirometry. 
5. Collect subject health care resource use information. 
6. Record any respiratory microbi ology results since Visit 1. 
7. If Chemistry tests for BUN, creatinine and seru m glucose have been collected for clinical 
care, obtain results and record. 
8. Record changes to concomitant medications.   
9. Perform abbreviated physical examination. 
10. Re-confirm eligibility. 
11. Enter required data into ED C for randomization (refer to CRF Completion Guidelines, 
includes CRISS and spirometry). 
12. Randomize subject to treatment duration.  
13. If able to expectorate, collect e xpectorated sputum  for microbiome. 
14. Collect blood and test for CRP at site. 
15. Collect blood and freeze serum for banking.  
16. Record any adverse events. 
17. Schedule subject for Visit 3 dependent on tr eatment arm and to occur 2 weeks after 
scheduled completion of IV treatment. 
10.3 Visit 3 (Follow-up 2 weeks a fter scheduled completion of  IV treatment /Day 24 – 35 
+/-2 days) 
1. Provide CFRSD Self-Report to  subject for completion. 
2. Provide EQ-5D-5L to subject for completion. 
3. Collect subject health care resource use information. 
4. Record any respiratory microbi ology results since Visit 1. 
5. If Chemistry tests for BUN, creatinine and seru m glucose have been collected for clinical 
care, obtain results and record. 
6. Record any adverse events.  
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 27 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 7. Record changes to concomitant medications. 
8. Perform abbreviated physical examination. 
9. Measure and record weight. 
10. Perform and record spirometry. 
11. If able to expectorate, collect e xpectorated sputum  for microbiome. 
12. Collect blood and test for CRP at site. 
13. Collect blood and freeze serum for banking. 
11 ADVERSE EXPERIENCE REPO RTING AND DOCUMENTATION 
11.1 Adverse Events 
An adverse event (AE) is any unt oward medical occurrence in a subj ect that is participating in 
this clinical investigat ion that is related to study participation (treatme nt arm assignment), study 
procedures, or any other si gnificant AE as determined by the investigator.   
AEs are defined as new or worsening of signs or symptoms, including clinically significant 
abnormal clinical laboratory values, that occur after randomization (Visit  2) until Visit 3.  
An unexpected AE is one of a type not identified in nature, severity, or frequency or of greater 
severity or frequency than expected.  
The Investigator will probe, via di scussion with the subject, for th e occurrence of AEs and record 
the information in the site’s source documents.  AEs will be recorded in the subject CRF.   
AE Severity The National Cancer Institute’s Common Termi nology Criteria for Adverse Events (CTCAE) 
Version 4.0, as modified for cystic fibrosis, s hould be used to assess and grade AE severity, 
including laboratory abnormalities judged to be clin ically significant. The modified criteria can 
be found in the Study Reference Binder.  If the expe rience is not covered in the modified criteria, 
the guidelines shown in Table 1 be low should be used to grade seve rity.  It should be pointed out 
that the term “severe” is  a measure of intensity and that a se vere AE is not necessarily serious. 
Table 1.  AE Severity Grading 
Severity (Toxicity Grade) Description 
Mild (1) Mild; asymptomatic or mild sy mptoms; clinical or diagnostic 
observations only; inte rvention not indicated 
Moderate (2)  Moderate; minimal, local or nonin vasive intervention indicated; 
limiting age-appropriate Instrumental activities of daily living (e.g., preparing meals, using th e telephone, managing money)  
Severe (3)  Severe or medically signifi cant but not immediately life-
threatening; hospitalization or prolongation of hospitalization 
indicated; disabling; limiting self  care activities of daily living 
(e.g., bathing, dressing, feeding self, using toilet, taking 
medications) 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 28 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 Life-threatening (4) Life-thr eatening consequences; urge nt intervention indicated 
Death (5) Death related to AE 
 
AE Relationship to Treatment Arm Assignment 
The relationship of an AE to the treatmen t arm assignment should be assessed using the 
following the guidelines in Table 2. 
Table 2.  AE Relationship to  Treatment Arm Assignment 
Relationship 
to Treatment  Comment 
Definitely An event that follows a reasonable temporal sequence from the clinical trial 
treatment arm assignment; that follows a known or expected response pattern 
to treatment arm assignment; and that is  not explained by any other reasonable 
hypothesis. 
Probably An event that follows a reasonable temporal sequence from the clinical trial 
treatment arm assignment; that follows a known or expected response pattern 
to treatment arm assignment; and that is  not explained by any other reasonable 
hypothesis; and that is unlik ely to be explained by the known characteristics of 
the subject’s clinical state or by other interventions. 
Possibly An event that follows a reasonable temporal sequence from the clinical trial 
treatment arm assignment; that follows a known or expected response pattern 
to treatment arm assignment; but that c ould readily have been produced by a 
number of other factors. 
Unrelated An event that can be determined with certainty to have no relationship to the 
treatment arm assignment. 
11.2 Serious Adverse Experiences (SAE) 
An SAE is defined as any AE occurring that  results in any of the following outcomes: 
 death 
 a life-threatening adverse experience 
 inpatient hospitalization (excluding the initial enrollment hospitalization) or hospitalizations 
that occur after the initial enrollment and star t of IV antibiotic treatment at home will be 
reported  
 prolongation of existing hosp italization beyond the planned duration as indicated by 
randomization 
 a persistent or significant disability/incapacity 
 a congenital anomaly/birth defect  
Other important medical events may also be considered an SAE when, based on appropriate 
medical judgment, they jeopardi ze the subject or requi re intervention to prevent one of the 
outcomes listed.  
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 29 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 11.2.1    Serious Adverse Experience Reporting 
Study sites will document all SAEs  that occur (whether or not related to treatment arm 
assignment) on an SAE Report Form.  The collection period for all SAEs will begin after informed consent is obtained and end after pr ocedures for the final study visit have been 
completed. 
All SAE Report Forms will be reviewed by the site  investigator and sent to the TDNCC within 
one business day of the site learning of the ev ent.  Sites will send the SAE report by either: 
 Email (scanned copy) to: cfsaesfacsys@seattlechildrens.org  
 TDNCC SAE Fax: (206) 985-3278 
The site will notify the TDNCC of additional in formation or follow-up to an initial SAE Report 
as soon as relevant information is availabl e.  The TDNCC Medical Monitor may request 
additional information related to the SAE. Follo w-up information is reported on an SAE Report 
Form. 
In accordance with the standard operating proced ures and policies of the local Institutional 
Review Board/Independent Ethics  Committee (IRB/IEC), the site investigator will report SAEs 
to the IRB/IEC.   
11.3 Medical Monitoring 
The TDNCC Medical Monitoring Gr oup should be contacted directly  at this number to report 
medical concerns or ques tions regarding safety: 
 (800) 341-0961  
12 DISCONTINUATION AND REPLACEMENT OF SUBJECTS 
12.1 Early Withdrawal of Subjects from the Study 
Early withdrawal of subjects may occur any time after the subject is rand omized.  All subjects 
are free to withdraw from partic ipation at any time, for any reas on, specified or unspecified, and 
without prejudice.  This may include subjects who withdraw from study treatment early and who 
decline to continue to come in for remaining follow-up visits or it may include subjects who 
completed treatment and decline to come in for remaining follow up visits.   
Reasonable attempts will be made by the invest igator to provide a reason for early subject 
withdrawals.  The reason for the subject’s earl y withdrawal from the study will be specified in 
the subject’s source documents.   
Subjects who fail to adhere to treatment durati on assignment are encouraged to complete all 
remaining study visits. Subjects should not be w ithdrawn for failure to adhere to treatment 
duration assignment. 
12.2 Replacement of Subjects 
Subjects who withdraw from the study will not be replaced.   
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 30 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 13 PROTOCOL VIOLATIONS 
A protocol violation occurs when the subject, in vestigator, or the Sponsor  fails to adhere to 
significant protocol requirements  affecting the inclusion, exclus ion, subject safety and primary 
endpoint criteria.  Protocol viol ations for this study include, but are not limited to, the following: 
 Failure to meet inclusion/exclusion criteria 
 Use of a prohibited concomitant medication 
 Failure to adhere to treatment duration assignment (within the pre-specified margins of 
acceptable durations) 
 Failure to perform spirometry at each study visit 
Failure to comply with Good Clinical Practice (GCP) guidelines will also  result in a protocol 
violation.  
When a protocol violation occurs, it will be di scussed with the investigator and a Protocol 
Violation Form detailing the violation will be ge nerated. This form will be signed by a Sponsor 
representative and the Investigat or. A copy of the form will be filed in the site’s regulatory 
binder and in the Sponsor’s files. The site will report the violation to their IRB/IEC in 
accordance with their IRB/IEC reporting requirements. 
14 DATA SAFETY MONITORING  
The Cystic Fibrosis Foundation DSMB will esta blish a Data Monitoring Committee (DMC) to 
review data relating to safety a nd efficacy, to conduct and review interim analyses, and to ensure 
the continued scientific valid ity and merit of the study, according to the Cystic Fibrosis 
Foundation DSMB Operations Manual and a DMC Ch arter created for this protocol.  Details 
regarding the timing and conten t of the interim reviews are included in Section 15.6, Interim 
Analysis below, the DMC Charter developed in conjunction with the DMC, and the Statistical 
Analysis Plan. 
SAEs will be monitored by the committee on an ongoing basis throughout the study. 
15 STATISTICAL METHODS AND CONSIDERATIONS 
A detailed Statistical Analysis Plan (SAP) will be written that will describe all analyses that will 
be generated for this study. All analyses will be performed using SAS® (SAS Institute, Inc., 
Cary, NC, USA) or R (R Foundation for Statisti cal Computing, Vienna, Austria). The SAP will 
contain any modifications to the an alysis plan described below.   
15.1 Data Sets Analyzed 
The primary NERR analyses will be performed us ing an intent-to-treat (ITT) population, which 
is defined as all subjects randomized at Visit 2. The analysis for NERR will be repeated in the 
per-protocol (PP) population, which is defined as  subjects in the I TT population who have no 
protocol violations as defined in Section 13. Th e primary ERR analyses will be performed using 
PP population; the analysis will be  repeated in the ITT population. 
Subjects who fail to adhere to treatment durati on assignment are encouraged to complete all 
remaining study visits and will remain in the analyses population according to ITT. 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 31 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 Handling of missing data will be outlined in the SAP, including sensitivity analyses. 
15.2 Demographic and Baseline Characteristics 
Treatment duration arms (ERR-10, ERR-14, NERR-14, NERR-21) within ERR and NERR 
groups will be described and compared with re spect to Baseline demographic and clinical 
characteristics including age, sex, CFTR genotype , race, height, weight, and all randomization 
strata.  For all analyses, Baseline clinical ch aracteristics will be defined as measurements 
obtained at Visit 1. 
15.3 Analysis of Primary Endpoint 
The primary endpoint is absolute change in percent predicted FEV 1 from Visit 1 (Baseline) to 
two weeks after scheduled completion of IV antib iotics (Visit 3). The primary endpoint will be 
compared between treatment durations with in ERR and NERR groups using Analysis of 
Variance (ANOVA) adjusted for dichotom ous randomization strata: Visit 1 FEV 1 , number of 
IV-treated exacerbations in prio r year, location of IV administration by Visit 2, and use of 
systemic corticosteroids by Visit 2.  
The treatment effect for each group (ERR and NERR) (estimated via adjusted ANOVA least 
squares means) will be presented along with corresponding 95% confidence intervals. Observed 
treatment effect and the 95% CI will provide primary inference and evidence of non-inferiority, 
superiority, or lack thereof in both the ERR and NERR groups.    
ERR Group: The non-inferiority of ERR-10 versus ERR-14 will be tested against a 3.5 % 
predicted non-inferiority margin with  a two-sided 0.05 level of significance.  
NERR Group: The superiority of NERR-21 versus NERR- 14 will be tested with a two-sided 0.05 
level of significance. 
Further details will be provided in the SAP, which will be finalized before the clinical data lock 
for the study. 
15.4 Analysis of Secondary Endpoints 
Descriptive analyses and graphica l displays will be used to summarize all secondary endpoints, 
including changes from baseline in continuous endpoints and rates over the follow-up period for 
event based endpoints.  The ITT and PP populations  will be used for all secondary analyses. 
All reported SAEs and AEs will be coded using MedDRA and grouped by body system.  (S)AEs 
will be tabulated by treatment durations with in ERR and NERR groups using standard coding 
terms sorted by body system.  The incidence of AEs (including emergent abnormal lab values collected for clinical care) in each treatmen t duration arm will be tabulated by seriousness, 
severity, and relationship to arm.  If an AE is reported more than once during the study period for 
a given subject, the greatest sever ity and the worst-case relationship will be presented in tables.  
The number of (S)AEs will be summarized by treatment duration arms within ERR and NERR 
groups as follows: (i) The proportion of subjects with at least one (S)A E, (ii) The average 
number of (S)AEs per patient, and (iii) The ra te of (S)AEs per patient month of follow-up.  
Histograms showing the frequency of the number of (S)AEs in each treatment duration arm will 
be included.  Rates of (S)AEs by System Organ Class (SOC) will be presented by treatment duration arm.  Poisson regression modeling will be used to derive rate ratios and 95% confidence 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 32 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 intervals for each SOC.  The rate ratios will be  compared using a two-sided 0.05 level test for 
Poisson count data. 
Descriptive summaries of antibiotics received by patients will be presen ted by treatment duration 
arm within ERR and NERR groups. Proportion of pa tients retreated with IV antibiotics (as 
collected in the CFFNPR) for pulmonary exacerbation within 30 days following scheduled 
completion of IV antibiotic treatment will be summarized by treatment duration arm within ERR 
and NERR groups and differences in the proporti on of subjects will be estimated and tested 
using a two-sided test of propor tions. Time (days) to next ex acerbation following scheduled 
completion of IV antibiotics will be presented using Kaplan-Meier survival estimation and 
compared between treatment durations within  ERR and NERR groups using a Cox proportional 
hazards model with a test of the treatment ef fect at a two-sided significance level of 0.05. The 
hazard ratio and its 95% confidence interval will be presented. An additional secondary analysis 
may stratify by or adjust for the randomization strata. 
Absolute change in CRISS, relative change in FEV 1 (liters), and absolute change in weight (kg) 
from Baseline (Visit 1) to two weeks after sche duled completion of IV antibiotics (Visit 3) will 
be summarized. Mean differences between tr eatment duration arms within ERR and NERR 
groups at each visit and correspond ing 95% CIs will be presented. Changes from Baseline (Visit 
1) to Visit 3 will be assessed using a two-sa mple, two-sided t-test and additional secondary 
analysis may adjust for the randomization strata. 
15.5 Analysis of Exploratory Endpoints 
The proportion of subjects discontinuing study before  versus after randomization and before the 
end of assigned treatment duration will be tabulated by reason for discontinuation and by 
treatment duration arm, if randomized.  Reason for discontinuations will be summarized. The 
screen failure reasons will be also summarized fo r all screening attempts. Characteristics of the 
un-randomized subjects by reason (e.g., lost to follow-up, missing FEV 1 or CRISS at Visit 2, 
patient withdrawal) will be summarized using descriptive characteristics.  Similarly, the 
randomized but lost to follow-up subjects (no Visi t 3) will be described.  Comparison of these 
two groups with the randomized completed subjects will be performed for baseline 
characteristics, treatments and outcomes utilizing both the study data and the CFFNPR.  
There will be descriptive summari es of adherence to antibiotic selection protocol and adherence 
to randomization scheme by response group (E RR and NERR), and treatment duration arm 
(ERR-10, ERR-14, NERR-14, and NERR-21). 
Descriptive comparisons of the two cohorts tr eated for 14 days (ERR-14 and NERR-14) will be 
performed to characterize associatio ns between early assessments of clinical response (at Visit 2) 
and after completion of treatment for a PEx (Visit 3). 
Clinical lab CRP at each of the study visits and change in CRP from Baseline (Visit 1) will be 
summarized by response group (ERR and NERR) a nd by treatment duration arm (ERR-10, ERR-
14, NERR-14, and NERR-21). Associations with  CRP and change in CRP with clinical 
outcomes will be examined. 
For all randomization arms (ERR-10, ERR- 14, NERR-14, and NERR-21), quality of life and 
medical cost metrics will be co llected for a comprehensive health economic analysis by Larry 
Kessler  ScD, Professor and Chair, Dept. of Hea lth Services, School of Public Health, University 
of Washington, Seattle according to the most rece nt guidance from the International Society for 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 33 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 Pharmacoeconomics and Outcomes  Research Good Research Pr actices for Cost-Effectiveness 
Analysis Alongside Clini cal Trials Task Force. 
For all treatment duration  arms (ERR-10, E RR-14, NERR-14, and NERR-21), the expectorated 
sputum will undergo analysis to describe a nd compare the respiratory microbiome by John 
Lipuma, MD, Professor of Pediatrics and Director of  Pediatric Infectious Diseases,  University of 
Michigan, Ann Arbor. 
15.6 Interim Analysis 
A pre-defined monitoring plan for feasibilit y, variance estimation, sample size adaptation, and 
study stopping rules will be formalized in conjun ction with the DMC and will be in place prior to 
initiating the study. Feasibility will be closely mo nitored for the first 100 enrolled patients to 
ensure adherence to protocol, return for random ization, and adherence to randomized treatment 
duration arm.  
Each treatment group (ERR and NERR) will have se parate monitoring criteria and a decision to 
stop one may not be conditional on the other. 
15.7 Sample Size  
ERR Group: 
A non-inferiority design to sh ow that the change in FEV 1 between Visit 1 and Visit 3 in the ERR 
subjects who received 10 days of treatment (ERR-10) is no more than 3.5 % predicted less than 
ERR subjects who received 14  days treatment (ERR-14) requires  310 subjects (155 per arm) who 
complete the study.  STOP  pilot data indicate a me an change (SD) in FEV 1 between baseline and 
Day 28 in patients with an early response to be 12.5 % predicte d, 95% CI [9.5, 15.6]. Assuming  
two-sided alpha =0.05, standard  deviation =9.0% predicted and the true difference between two 
groups is zero, the ERR study has 93% power to detect a 3.5 % non-infe riority margin which 
preserves 72% of the treatment effect or 63% of the lower bound of treatment effect observed in 
the STOP pilot.   
NERR Group: A superiority design to show  that the ch ange in FEV
1 between Visit 1 and Visit 3 in NERR 
subjects who received 21 days treat ment (NERR-21) is at least 2.5 % predicted greater than NERR 
subjects who received 14 days tr eatment (NERR-14) requ ires 570 subjects (285 per arm) who 
complete the study.  STOP  pilot data indicate a me an change (SD) in FEV 1 between baseline and 
Day 28 in patients without an early response to be  4.0 % predicted, 95% CI  [1.9, 6.1].  Assuming 
two-sided alpha =0.05 and standa rd deviation =9.0% predicted, th e NERR study has 91% power to 
detect a 2.5% or greater increase in FEV 1 among those treated with 21 days compared to 14 day 
IV antibiotic. A 2.5% improvement was chosen to represent a minimal clinically important 
difference in lung function to justify the additiona l burden and potential toxicity of 21 days of 
treatment versus 14.  It is important to note that  statistical significance can be shown at the end 
of the superiority NERR study with a smaller treatment effect than 2.5%. 
Observed treatment effect (mean difference in absolute FEV 1 change) and the 95% CI will 
provide primary inference and evidence of non-infe riority, superiority, or lack thereof in both 
the ERR and NERR groups. Motivated to ensure conclusive results, this study was designed to 
provide sufficiently narrow 95%  CIs at the end of the trial (ERR 95% CI half-width=2%; 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 34 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 NERR 95% CI half-width=1.5% when both SD=9%).  
Because this trial will enroll a slightly different patient popul ation (including ho me IV, excluding 
patients who receive <7 days of IV antibiotics), a blinded, interim assess ment of change in FEV 1 
% predicted and variance (pooled) will be perfor med and expected sample size may be adjusted 
for either the ERR or NERR groups.  
Based on STOP pilot da ta, we anticipate 1:2 allocation of subject s into the ERR and NERR  
groups. To meet the enrollment goal of a minimum of 310 completed ERR subjects and a 
minimum of 570 completed NERR subjects, we will screen  approximately 1330 subjects. Of 
these, we expect appr oximately 1236 s ubjects will be enrolled and randomized (assuming a 
conservative 7% drop-out rate between Visit 1 and Visit 2) and a minimum of 310 completed ERR subjects and a minimum of 570 completed NERR subjects (assuming an approximate 4% drop-out rate between Visit 2 and Visit 3).  
16 DATA COLLECTION, RETENTION AND CLINICAL MONITORING 
16.1 Data Collection Instruments 
The Investigator will prepare and maintain adeq uate and accurate source documents designed to 
record all observations and othe r pertinent data for each subject who signs informed consent.  
Study personnel at each site will enter data fr om source documents corresponding to a subject’s 
visit into the protocol-specific electronic CRF when the informati on corresponding to that visit is 
available.  Subjects will not be identified by name in the study database or on any study 
documents to be collected by the Sponsor (or de signee), but will be identified by a site number, 
subject number and, for US sites only, initials. 
If a correction is required for a CRF, the time  and date stamp tracks the person entering or 
updating CRF data and creates an electronic audit trail.   
The Investigator is responsible for all informati on collected on subjects enrolled in this study.  
All data collected during  the course of this study must be re viewed and verified for completeness 
and accuracy by the Investigator.  A CD containing the CRF data will be pr ovided to the site to 
be retained with the essential documents at the I nvestigator’s site at the completion of the study.  
16.2 Data Management Procedures 
TDNCC utilizes Medidata Solutions, Inc. (Medid ata) Rave for their ED C studies. The Medidata 
Rave EDC system is designed to be US Code  of Federal Regulations (CFR) 21 Part 11 
compliant, with a robust audit tr ail system and electronic signat ure capabilities.  Study personnel 
at each site will enter data from a subject’s vis it onto electronic CRF screens via a web browser.  
Study subjects will not be iden tified by name in the study data base or on any data capture 
screens, but will be identified by initials and a unique subject identification number.  Only study 
personnel at the individual sites will be able to link the study ID  to the subject’s name.  The 
Biostatistics and Clinical Data Management gr oup of the TDNCC will be responsible for data 
processing, in accordance with procedural documentation.  Database lock will occur once quality assurance procedures have been completed.  All pr ocedures for the handling and analysis of data 
will be conducted using good computing practices for the handling and analysis of data for 
clinical trials.   
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 35 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 16.3 Data Quality Control and Reporting 
After data have been entered into the study data base, data validation checks will be applied on a 
regular basis. Queries are ente red, tracked, and resolved thro ugh the EDC system directly.  The 
study database will be updated in accordance with  the resolved queries. All changes to the study 
database will be documented in an audit trail. 
16.4 Security and Archival of Data 
The EDC system is hosted by Medida ta; the data are stored at Medi data’s primary data center in 
Houston, Texas, with fail-safe data centers in  New Jersey.  Data are regularly backed up by 
Medidata. 
Medidata maintains 21 CFR Part 11-compliant elect ronic systems, with pr ocedures in place to 
safeguard against unauthorized acquisition of data.  Any aut horized communication with the 
Medidata servers at the Houst on Data Center is conducted via SSL (128-bit) encryption.  Robust 
password procedures, consistent with 21 Part  11, are in place.  Robust physical security 
procedures are in place at the Houston Data Ce nter to prevent unauthorized personnel physical 
access to the server rooms.  EDC account access is maintained and monitored by the Biostatistics 
and Clinical Data Manage ment group of the TDNCC. 
Other databases will be stor ed on Seattle Children’s server s and are safeguarded against 
unauthorized access by established security pr ocedures.  Network accounts are password 
protected and maintained and monitored by th e Seattle Children’s Information Technology 
group.  Data is backed up regularly according to  the Information Servi ces group’s procedures.  
Note that there is an intention to make bi ospecimens and associat ed data available to 
investigators for future exploration. The biospeci mens will be collected under IRB/IEC approval, 
processed according to a rigorous standard operating procedure and stored at a central facility, 
with appropriate procedures to enable long term, stable storag e. Researchers may apply, via a 
standardized process, for use of de-identif ied data and specimens for research purposes. 
Applications will undergo a scie ntific review process admini stered through CFFT. When 
applying for use of data or specimens, the ap plicant must agree to: (1) use the data and 
specimens only for research purposes and to not  make any attempts to try to identify any 
individual subject; (2) securing the data and specimens us ing appropriate methods; and (3) 
destroy or return the data (and specimens) in accordance with the specimen/data use agreement 
after analyses are completed.  Before data or specimens will be released to an investigator, 
documentation of IRB/IEC exemption or approval fr om their institution must be provided to the 
CFFT. 
16.5 Availability and Retention of Investigational Records 
The Investigator must make study data acce ssible to the monitor, other authorized 
representatives of the Sponsor (or designee), IRB/IEC, and Regulatory Agency (e.g., FDA) 
inspectors upon request.  A file for each subjec t must be maintained that includes the signed 
Informed Consent, HIPAA Authorization and Assent Form and copies of all source 
documentation related to that subject.  The I nvestigator must ensure the reliability and 
availability of source documents from whic h the information on the CRF was derived. 
All study documents (e.g., patient files, signed informed consent forms, copies of CRFs, 
Essential Document and Study Reference Binders) mu st be kept secured for a period of one year 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 36 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 after database lock and accessible for 5 years following database lock.  There may be other 
circumstances for which the Sponsor is required  to maintain study records and, therefore, the 
Sponsor should be contacted prior to  removing study records for any reason. 
16.6 Monitoring 
By signing this protocol, the Investigator gran ts permission to the Sponsor (or designee), and 
appropriate regulatory authorities to conduct on-site monitoring and/ or auditing of all appropriate 
study documentation.  
16.7 Subject Confidentiality 
In order to maintain subject c onfidentiality, only a site number, subject number, subject initials 
(US sites only) and subject’s CFF patient regist ry number (US sites only) will identify all study 
subjects on CRFs and other documentation subm itted to the Sponsor.   Additional subject 
confidentiality issues (if a pplicable) are covered in th e Clinical Study Agreement. 
17 ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS 
The study will be conducted according to the De claration of Helsinki , Protection of Human 
Volunteers (21 CFR 50), Instituti onal Review Boards (21 CFR 56), and Obligations of Clinical 
Investigators (21 CFR 312). 
To maintain confidentiality, all laboratory specimens, evaluation forms, reports and other records 
will be identified by a coded number and initials only.  Clinical information will not be released 
without written permission of the subject, except as necessary for monitoring by the FDA.  The 
Investigator must also comply with all applicable privacy regu lations (e.g., Health Insurance 
Portability and Accountability Act of 1996). 
17.1 Protocol Amendments 
Any amendment to the protocol will be written by the Sponsor.  Protocol amendments cannot be 
implemented without prior written IRB/IEC approva l except as necessary to eliminate immediate 
safety hazards to patients.  A protocol amendm ent intended to eliminate an apparent immediate 
hazard to patients may be implemented immediatel y, provided the IRBs/IECs are notified within 
five working days. 
17.2 Institutional Review Boards  
The protocol and consent form will be reviewed and approved by the IRB/IEC of each 
participating center prior to study initiation.  SAEs  regardless of causality will be reported to the 
IRB/IEC in accordance with the standard operating procedures and policies of the IRB/IEC, and 
the Investigator will keep the IRB/IEC informed as  to the progress of the study.  The Investigator 
will obtain assurance of IRB/IEC compliance with regulations. 
Any documents that the IRB/IEC may need to fu lfill its responsibilities (such as protocol, 
protocol amendments, consent forms, informati on concerning patient recruitment, payment or 
compensation procedures, or other pertinent informa tion) will be submitted to the IRB/IEC.  The 
IRB/IEC’s written unconditional approval of the study protocol and the informed consent form will be in the possession of the Investigator before the study is initiated.  The IRB/IEC’s 
unconditional approval statement will be tran smitted by the Investigator to the Sponsor or 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 37 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 designee prior to the shipment of study supplies to the site.  This approval must refer to the study 
by exact protocol title and numb er and should identify the documen ts reviewed and the date of 
review. 
Protocol and/or informed consent modifications or changes may not be initiated without prior 
written IRB/IEC approval except wh en necessary to eliminate imme diate hazards to the patients 
or when the change(s) involves only logistical or administrativ e aspects of the study.  Such 
modifications will be submitted to the IRB/IEC and written verification that the modification was submitted and subsequently approved should be obtained.   
The IRB/IEC must be informed of revisions to other documents originally submitted for review; 
serious and/or unexpected advers e experiences occurri ng during the study in accordance with the 
standard operating procedures and policies of the IRB/IEC; ne w information that may affect 
adversely the safety of the patients of the conduc t of the study; an annual update and/or request 
for re-approval; and when the study has been completed. 
17.3 Informed Consent Form  
Informed consent will be obtained in accordance w ith the Declaration of Helsinki, ICH GCP, US 
Code of Federal Regulations for Protecti on of Human Subjects (21 CFR 50.25[a,b], CFR 50.27, 
and CFR Part 56, Subpart A), the Health Insura nce Portability and Accountability Act (HIPAA, 
if applicable), and local regulations. 
The Investigator will prepare the informed c onsent form, assent (if applicable) and HIPAA 
authorization (if applicable) and provide the do cuments to the Sponsor or designee for approval 
prior to submission to the IRB/IEC.  The consen t form generated by the Investigator must be 
acceptable to the Sponsor and be approved by the IRB/IEC.  The written  consent document will 
embody the elements of informed consent as de scribed in the Intern ational Conference on 
Harmonisation and will also comply with local re gulations. The Investigator will send an IRB-
approved copy of the Informed Consent Form to the Sponsor (or designee) for the study file. 
A properly executed, written, informed consent w ill be obtained from each subject prior to 
entering the subject into the trial.  Information should be given in both oral and written form and 
subjects must be given ample opportunity to inqu ire about details of th e study.  If appropriate 
and required by the local IRB/IEC, assent from the subject will also be obtained.  If a subject is 
unable to sign the informed consent form and the HIPAA authorization, a legal representative 
may sign for the subject.   A copy of the signed consent form (and assent) will be given to the 
subject of the subject and the original will be maintained with the subject’s records. 
During the course of the study, if modifications ar e made to the consent form that impact the 
subject, the subject will be re -consented as described above.  
17.4 Consent for Collection and Use of CFF Registry ID Number (US Sites Only) 
To facilitate future evaluation of retrospective and prospective information from all patients who 
screen for this study, the subject’s CFF Registry  ID number will be collected.  The CFFNPR 
collects data on all CF patient s who consented to participat e in the CFFNPR and who are 
followed at CFF-accredited care centers.  The regi stry data includes information from clinical 
encounters, hospitalizations cour ses of antibiotics, and year-end surveys.  Data also include 
microbiology results, spirometry results, CF genot ype and other information such as survival.  
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 38 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 17.5 Publications  
The preparation and submittal for publication of manuscripts contai ning the study results shall be 
in accordance with a process determined by mutual written agreement among the study Sponsor and participating institutions.  Th e publication or presentation of  any study results shall comply 
with all applicable privacy laws, including, but not limited to, the Health  Insurance Portability 
and Accountability Act of 1996. 
17.6 Investigator Responsibilities 
By signing the Agreement of Investigator  form, the Investigator agrees to: 
1. Conduct the study in accordance with the protoc ol and only make changes after notifying the 
Sponsor (or designee), except when to protect the safety, rights or welfare of subjects. 
2. Personally conduct or supervise the study (or investigation). 
3. Ensure that the requirements relating to obtaini ng informed consent and IRB/IEC review and 
approval meet federal guidelines, as stated in § 21 CFR, parts 50 and 56. 
4. Report to the Sponsor or desi gnee any AEs that occur in the course of the study, in 
accordance with §21 CFR 312.64. 
5. Ensure that all associates, colleagues and empl oyees assisting in the conduct of the study are 
informed about their obligations in meeting the above commitments. 
6. Maintain adequate and accura te records in accordance with  §21 CFR 312.62 and to make 
those records available for inspection with the Sponsor (or designee). 
7. Ensure that an IRB/IEC that complies with  the requirements of §21 CFR part 56 will be 
responsible for initial and continuing review and appr oval of the clinical study. 
8. Promptly report to the IRB/IEC and the Sponsor  (or designee) all cha nges in the research 
activity and all unanticip ated problems involving risks to subjects or others (to include 
amendments). 
9. Seek IRB/IEC approval before any changes ar e made in the research study, except when 
necessary to eliminate hazards to the patients/subjects. 
10. Comply with all other requirement s regarding the obligations of clinical investigators and all 
other pertinent requirements listed in § 21 CFR part 312. 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 39 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 18 REFERENCES 
1. Bradley J, McAlister O, Elborn S. Pulmonary  function, inflammation, exercise capacity and 
quality of life in cystic fibrosis. Eur Respir J  2001; 17(4): 712-5. 
2. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of 
recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest  
2002; 121(1): 64-72. 
3. Orenstein DM, Pattishall EN, Nixon PA, Ro ss EA, Kaplan RM. Quality of well-being 
before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis. Chest  1990; 98(5): 1081-4. 
4. Konstan MW, Morgan WJ, Butler SM, et al. Ri sk factors for rate of decline in forced 
expiratory volume in one second in childre n and adolescents with cystic fibrosis. J Pediatr  
2007; 151(2): 134-9, 9 e1. 
5. Ellaffi M, Vinsonneau C, Coste J, et al . One-year outcome after severe pulmonary 
exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med  2005; 171(2): 158-
64. 
6. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa 
and other predictors of mort ality and morbidity in young chil dren with cystic fibrosis. 
Pediatr Pulmonol  2002; 34(2): 91-100. 
7. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year 
survivorship model of cystic fibrosis. Am J Epidemiol  2001; 153(4): 345-52. 
8. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic 
fibrosis lung transplant re ferral criteria using predic tors of 2-year mortality. Am J Respir 
Crit Care Med  2002; 166(12 Pt 1): 1550-5. 
9. Wagener JS, Rasouliyan L, VanDevanter DR, et  al. Oral, inhaled, and intravenous antibiotic 
choice for treating pulmonary exa cerbations in cystic fibrosis. Pediatr Pulmonol  2013; 
48(7): 666-73. 
10. VanDevanter DR, Yegin A, Morgan WJ, Millar SJ, Pasta DJ, Konstan MW. Design and 
powering of cystic fibrosis clinical trials  using pulmonary exacerbation as an efficacy 
endpoint. Journal of cystic fibrosis : official journal of the Eu ropean Cystic Fibrosis Society  
2011; 10(6): 453-9. 
11. VanDevanter DR, O'Riordan MA, Blumer JL , Konstan MW. Assessing time to pulmonary 
function benefit following antibiotic treatment  of acute cystic fibrosis exacerbations. Respir 
Res 2010; 11: 137. 
12. Flume PA, Mogayzel PJ, Jr., Robinson KA, et  al. Cystic fibrosis pulmonary guidelines: 
treatment of pulmonary exacerbations. Am J Respir Crit Care Med  2009; 
180(9): 802-8. 
13. Rabin HR, Butler SM, Wohl ME, et al. Pulm onary exacerbations in cystic fibrosis. Pediatr 
Pulmonol  2004; 37(5): 400-6. 
14. Regelmann WE, Elliott GR, Warwick WJ, Claw son CC. Reduction of sputum Pseudomonas 
aeruginosa density by antibiotics improves lung f unction in cystic fibrosis more than do 
bronchodilators and chest physiotherapy alone. Am Rev Respir Dis  1990; 141(4 Pt 1): 914-
21. 
15. Cystic Fibrosis Foundation Patient Regist ry 2011 Annual Data Report to the Center 
Directors. 2012. 
16. Sanders DB, Bittner RC, Rosenfeld M, Ho ffman LR, Redding GJ, Goss CH. Failure to 
recover to baseline pulmonary function af ter cystic fibrosis pulmonary exacerbation. Am J 
Respir Crit Care Med  2010; 182(5): 627-32. 
STOP2-IP-15 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 40 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 17. Smith AL, Doershuk C, Goldmann D, et al. Co mparison of a beta-lactam alone versus beta-
lactam and an aminoglycoside for pulmona ry exacerbation in cystic fibrosis. J Pediatr  1999; 
134(4): 413-21. 
18. Quanjer PH, Stanojevic S, Cole TJ, et al. Mu lti-ethnic reference values for spirometry for 
the 3-95-yr age range: the gl obal lung function 2012 equations. Eur Respir J  2012; 40(6): 
1324-43. 
19. Stanojevic S, Wade A, Stocks J, et al. Re ference ranges for spirometry across all ages: a 
new approach. Am J Respir Crit Care Med  2008; 177(3): 253-60. 
 
STOP2 Confidential 
Version # 3 A Version Date: November 2, 2018 Page 41 of 41 
Protocol Template:  © CFFT TDN   Effective: 09 JUN 2015 19 APPENDIX 1. SCHEDULE OF EVENTS 
 Visit 1 Visit 2 Visit 3 1 
Event/Assessment Day 1 4 Between Day 7 
- 10 of IV 
Antibiotics 
(±1 days)  Between Day 24 - 35 
2 wks after scheduled 
completion of IV 
treatment  
(+/-2 days) 
Informed Consent X   
Medical History, Demographics, CF 
Diagnosis, CF Registry ID X   
Collect subject health care resource use X 2 X 3 X 3 
Concomitant Medication Review  X X X 
Collect results of clinical care respiratory 
cultures for microbiology X   
Collect results of clinical care BUN, 
creatinine and serum glucose X   
Subject Questionnaire: CRISS  X X  
Subject Questionnaire: CFRSD   X 
Subject Questionnaire: EQ-5D-5L X X X 
Complete Physical Exam X   
Abbreviated Physical Exam  X X 
Height  X   
Weight X X X 
Spirometry X X X 
Collect sputum for microbiome  X X X 
Collect blood and test for  CRP at site   X X X 
Collect blood and freeze serum for banking  X X X 
Complete Signs and Symptoms Assessment X   
Allocation to group and Randomization to IV 
treatment duration   X  
Adverse Event Review  X X 
1 Visit day will vary, depende nt on group and duration arm 
2 Subject and care-giver job classifications  
3  Subject-reported travel time to visits, IV treatment times, car egiver care times, additional clinic visits. At Visit 3, only H ealth Care Resource 
Use information that was not previously co llected or has changed since data was co llected at Visit 2 will be collected.   
4  Day 1 is defined as the day that IV antibiotics are initiated . Visit 1 may occur up to three days prior to the initiation of IV antibiotics or up to 1 
calendar day after IV antibiotics are initiated. 